Covered recipient · General Payments record
GERALD A LEVINE
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
General Payments · PY2018–2024
$110,495.26
- Reported across 355 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $927.58 | 27 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $299.55 | 9 |
| Novo Nordisk AS | $211.01 | 6 |
| Abbott Laboratories | $192.15 | 3 |
| ABBVIE INC. | $80.55 | 3 |
| MannKind Corporation | $67.75 | 3 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $28.79 | 1 |
| Ascendis Pharma Inc | $28.48 | 1 |
| Amgen Inc. | $19.30 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (27)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $28.63 | 05/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125102064 | CMS |
| Abbott Laboratories | $142.47 | 11/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125102066 | CMS |
| Abbott Laboratories | $21.05 | 12/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125102068 | CMS |
| ABBVIE INC. | $34.19 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104166444 | CMS |
| ABBVIE INC. | $23.59 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104166446 | CMS |
| ABBVIE INC. | $22.77 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104166448 | CMS |
| Amgen Inc. | $19.30 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111633502 | CMS |
| Ascendis Pharma Inc | $28.48 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133850994 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $28.79 | 03/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118039190 | CMS |
| Lilly USA, LLC | $26.16 | 02/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134999674 | CMS |
| Lilly USA, LLC | $27.00 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135000994 | CMS |
| Lilly USA, LLC | $121.13 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134987354 | CMS |
| Lilly USA, LLC | $17.18 | 07/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134987352 | CMS |
| Lilly USA, LLC | $22.59 | 07/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135007957 | CMS |
| Lilly USA, LLC | $28.38 | 07/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134987356 | CMS |
| Lilly USA, LLC | $28.94 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134977934 | CMS |
| Lilly USA, LLC | $1.67 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134977936 | CMS |
| Lilly USA, LLC | $26.50 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135006413 | CMS |
| Mannkind Corporation | $21.12 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145845373 | CMS |
| Mannkind Corporation | $21.64 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145845375 | CMS |
| Mannkind Corporation | $24.99 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145845377 | CMS |
| Novo Nordisk Inc | $25.00 | 02/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096588477 | CMS |
| Novo Nordisk Inc | $16.67 | 04/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096587457 | CMS |
| Novo Nordisk Inc | $15.75 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097045526 | CMS |
| Novo Nordisk Inc | $22.74 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097600848 | CMS |
| Novo Nordisk Inc | $10.00 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097101349 | CMS |
| Novo Nordisk Inc | $120.85 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096607463 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.